Identification and Estimation of Causal Effects Using Non‐Concurrent Controls in Platform Trials
Statistics in Medicine · 2025
DOI: 10.1002/sim.70017 ↗At a glance
Journal article in Statistics in Medicine, 2025. Written by Michele Santacatterina and 3 co-authors. Institution: Division of Biostatistics, Department of Population Health, New York University School of Medicine, New York, New York, USA. Major MEDLINE topics: Causality, Randomized Controlled Trials as Topic. Cited 1 times so far (Crossref); 52 references. The full text is freely available in PubMed Central. Funded by: NIAID NIH HHS, National Science Foundation, National Science Foundation of Sri Lanka.
Abstract (original language)
Platform trials are multi‐arm designs that simultaneously evaluate multiple treatments for a single disease within the same overall trial structure. Unlike traditional randomized controlled trials, they allow treatment arms to enter and exit the trial at distinct times while maintaining a control arm throughout. This control arm comprises both concurrent controls, where participants are randomized concurrently to either the treatment or control arm, and non‐concurrent controls, who enter the trial when the treatment arm under study is unavailable. While flexible, platform trials introduce the challenge of using non‐concurrent controls, raising questions about estimating treatment effects. Specifically, which estimands should be targeted? Under what assumptions can these estimands be identified and estimated? Are there any efficiency gains? In this article, we discuss issues related to the identification and estimation assumptions of common choices of estimand. We conclude that the most robust strategy to increase efficiency without imposing unwarranted assumptions is to target the concurrent average treatment effect (cATE), the ATE among only concurrent units, using a covariate‐adjusted doubly robust estimator. Our studies suggest that, for the purpose of obtaining efficiency gains, collecting important prognostic variables is more important than relying on non‐concurrent controls. We also discuss the perils of targeting ATE due to an untestable extrapolation assumption that will often be invalid. We provide simulations illustrating our points and an application to the ACTT platform trial, resulting in a 20% improvement in precision compared to the naive estimator that ignores non‐concurrent controls and prognostic variables.
Subjects
MeSH terms (MEDLINE)
Author keywords
Authors and institutions
- Division of Biostatistics, Department of Population Health, New York University School of Medicine, New York, New York, USA.
ORCID profiles: Michele Santacatterina
Funding
- NIAID NIH HHS
- National Science Foundation
- National Science Foundation of Sri Lanka
Cite
APA
Santacatterina, M., Giron, F. M., Zhang, X., & Díaz, I. (2025). Identification and Estimation of Causal Effects Using Non‐Concurrent Controls in Platform Trials. Statistics in Medicine. https://doi.org/10.1002/sim.70017
Vancouver
Santacatterina M, Giron FM, Zhang X, Díaz I. Identification and Estimation of Causal Effects Using Non‐Concurrent Controls in Platform Trials. Statistics in Medicine. 2025. doi:10.1002/sim.70017
BibTeX
@article{Santacatterina2025,
author = {Santacatterina, Michele and Giron, Federico Macchiavelli and Zhang, Xinyi and Díaz, Iván},
title = {Identification and Estimation of Causal Effects Using Non‐Concurrent Controls in Platform Trials},
journal = {Statistics in Medicine},
year = {2025},
doi = {10.1002/sim.70017}
}
EUVIMED